Antivirals

Antivirals Reactions 1704, p43 - 2 Jun 2018 Viral resistance and treatment failure secondary to acquired gene mutation: 23 case reports In a study, 23 patients [ages and sexes not stated] developed viral resistance and treatment failure secondary to acquired gene mutation following direct acting antiviral (DAA) therapy with asunaprevir, beclabuvir, daclatasvir, ledipasvir, peginterferon, ribavirin, simeprevir or sofosbuvir for chronic genotype 1b hepatitis-C virus (HCV) infection [routes, dosages and durations of treatments to reactions onsets not stated]. The patients, who had chronic genotype 1b hepatitis-C virus (HCV) infection, and who had failed to respond to prior DAA treatment were enrolled in a study. Of these, 16 patients had received prior DAA treatment with daclatasvir plus asunaprevir, two patients had received simeprevir plus peg- interferon and ribavirin, which was later switched to daclatasvir plus asunaprevir, one patient had received daclatasvir plus asunaprevir, which was later switched to ledipasvir plus sofosbuvir and that was again switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received daclatasvir plus asunaprevir, which was later switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received ledipasvir plus sofosbuvir, which was later switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received ledipasvir plus sofosbuvir, which was later switched to ledipasvir plus sofosbuvir, and the remaining one patient had received simeprevir plus peg-interferon and ribavirin, which was later switched to daclatasvir plus asunaprevir, that was again changed to ledipasvir plus sofosbuvir, and that was again switched to daclatasvir, asunaprevir plus beclabuvir. Subsequently, 16 patients developed relapse of HCV infections after the cessation of the DAA treatment, and remaining seven patients developed breakthrough HCV infections during the DAA treatment. The DAA therapy was eventually stopped in the seven patients, who developed breakthrough HCV infections during the therapy. After 1–38 months of end of the DAA therapy (at the current presentation), a gene analysis was performed, which revealed presence of treatment-emergent drug resistance-associated variants (RAVs). It was determined that this acquired gene mutation had caused resistance to the DAA treatment resulting in treatment failure. Author comment: "A substantial number of patients who have failed prior DAA treatments acquire RAVs. Treatment- emergent NS5A-RAVs, in particular, are known to persist for a long time, suggesting that they do not impose a high fitness trade off." "According to our findings and previous reports, RAVs present after failure of DAA treatment may reflect complex patterns and remain refractory to DAA re-treatment." Teraoka Y, et al. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochemical and Biophysical Research Communications 500: 152-157, No. 2, 2 Jun 2018. Available from: URL: https:// doi.org/10.1016/j.bbrc.2018.04.005 - Japan 803323778 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antivirals

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/antivirals-44mDFiYlhn
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46686-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p43 - 2 Jun 2018 Viral resistance and treatment failure secondary to acquired gene mutation: 23 case reports In a study, 23 patients [ages and sexes not stated] developed viral resistance and treatment failure secondary to acquired gene mutation following direct acting antiviral (DAA) therapy with asunaprevir, beclabuvir, daclatasvir, ledipasvir, peginterferon, ribavirin, simeprevir or sofosbuvir for chronic genotype 1b hepatitis-C virus (HCV) infection [routes, dosages and durations of treatments to reactions onsets not stated]. The patients, who had chronic genotype 1b hepatitis-C virus (HCV) infection, and who had failed to respond to prior DAA treatment were enrolled in a study. Of these, 16 patients had received prior DAA treatment with daclatasvir plus asunaprevir, two patients had received simeprevir plus peg- interferon and ribavirin, which was later switched to daclatasvir plus asunaprevir, one patient had received daclatasvir plus asunaprevir, which was later switched to ledipasvir plus sofosbuvir and that was again switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received daclatasvir plus asunaprevir, which was later switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received ledipasvir plus sofosbuvir, which was later switched to daclatasvir, asunaprevir plus beclabuvir, one patient had received ledipasvir plus sofosbuvir, which was later switched to ledipasvir plus sofosbuvir, and the remaining one patient had received simeprevir plus peg-interferon and ribavirin, which was later switched to daclatasvir plus asunaprevir, that was again changed to ledipasvir plus sofosbuvir, and that was again switched to daclatasvir, asunaprevir plus beclabuvir. Subsequently, 16 patients developed relapse of HCV infections after the cessation of the DAA treatment, and remaining seven patients developed breakthrough HCV infections during the DAA treatment. The DAA therapy was eventually stopped in the seven patients, who developed breakthrough HCV infections during the therapy. After 1–38 months of end of the DAA therapy (at the current presentation), a gene analysis was performed, which revealed presence of treatment-emergent drug resistance-associated variants (RAVs). It was determined that this acquired gene mutation had caused resistance to the DAA treatment resulting in treatment failure. Author comment: "A substantial number of patients who have failed prior DAA treatments acquire RAVs. Treatment- emergent NS5A-RAVs, in particular, are known to persist for a long time, suggesting that they do not impose a high fitness trade off." "According to our findings and previous reports, RAVs present after failure of DAA treatment may reflect complex patterns and remain refractory to DAA re-treatment." Teraoka Y, et al. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochemical and Biophysical Research Communications 500: 152-157, No. 2, 2 Jun 2018. Available from: URL: https:// doi.org/10.1016/j.bbrc.2018.04.005 - Japan 803323778 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off